Inhibition of HDAC and mTOR may improve outcomes for relapsed/refractory Hodgkin lymphoma

(American Association for Cancer Research) The histone deacetylase (HDAC) inhibitor vorinostat (Zolinza) in combination with the mTOR inhibitor sirolimus (Rapamune) or everolimus (Afinitor) showed clinical efficacy in patients with relapsed/refractory Hodgkin lymphoma, according to results from a phase I clinical trial.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news